A nanoparticle-based vaccine candidate for H5N1 avian influenza achieved 100% protection in preclinical trials, offering hope ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Proven effective for COVID-19, vaccine platform could be key in responding to evolving bird flu strains A developmental ...

To create the experimental bird flu vaccine, the researchers added what’s called a histidine tag, or his-tag, to both the H5 ...

Over the past years, China has achieved notable breakthroughs in vaccine technology. Milestones include the successful ...

BUFFALO-NIAGARA, N.Y., April 17, 2025 /CNW/ - As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off POP ...

Lead researcher and CEO of POP Biotechnologies, Dr. Jonathan Lovell is based at the University at Buffalo. Dr. Lovell said ...

In results published today in Cell Biomaterials, an international team reported that a nanoparticle vaccine displaying two recombinant virus-derived proteins; hemagglutinin (H5) and neuraminidase (N1) ...